Cart
sales@molnova.com
Kakkalide
CAS No. 58274-56-9
Kakkalide( —— )
Catalog No. M24574 CAS No. 58274-56-9
Kakkalide is a potent lactate dehydrogenase (LDH) inhibitor, it has anti-inflammatory effects.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 396 | In Stock |
|
| 10MG | 591 | In Stock |
|
| 25MG | 942 | In Stock |
|
| 50MG | 1237 | In Stock |
|
| 100MG | 1655 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameKakkalide
-
NoteResearch use only, not for human use.
-
Brief DescriptionKakkalide is a potent lactate dehydrogenase (LDH) inhibitor, it has anti-inflammatory effects.
-
DescriptionKakkalide is a potent lactate dehydrogenase (LDH) inhibitor, it has anti-inflammatory effects.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetDehydrogenase
-
RecptorLDH
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number58274-56-9
-
Formula Weight608.6
-
Molecular FormulaC28H32O15
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESO=C1C2=C(O)C(OC)=C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)CO[C@H]4[C@@H]([C@H]([C@H](O)CO4)O)O)C=C2OC=C1C5=CC=C(OC)C=C5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Kakkalide ameliorates endothelial insulin resistance by suppressing reactive oxygen species-associated inflammation.J Diabetes. 2013 Mar;5(1):13-24.
molnova catalog
related products
-
Mycophenolic acid
Mycophenolic acid is an an immunosuppresant drug and has potent anti-proliferative activity.
-
IDH889
IDH889 is a brain penetrant, an allosteric and mutant specific IDH1 inhibitor. IDH889 has effective selectivity for IDH1 R132* mutations (IC50s: 0.02 μM, 0.072 μM, and 1.38 μM for IDH1R132H, IDH1R132C, and IDH1wt).
-
AGI-5198
AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.
